Ignite Creation Date:
2024-05-05 @ 11:45 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00128791
Status:
TERMINATED
Last Update Posted:
2007-05-25
First Post:
2005-08-09
Brief Title:
Nitroprusside for Prevention of no-Reflow in Primary Angioplasty
Sponsor:
Soroka University Medical Center
Organization:
Soroka University Medical Center
Study Overview
Official Title:
Intracoronary Nitroprusside for the Prevention of the No-Reflow Phenomenon Following Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction A Randomized Double Blind Placebo-Controlled Clinical Trial
Status:
TERMINATED
Status Verified Date:
2007-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In patients admitted with acute myocardial infarction there is a total occlusion of a coronary artery Even after emergency catheterization and angioplasty in some patients the resumed blood flow is suboptimal and impacts on heart function The study is aimed at examining whether nitroprusside an anti-hypertension medication given directly into the coronary artery can improve the blood flow after the removal of the obstruction that caused the infarction
Detailed Description:
Inadequate myocardial tissue perfusion despite successful relief of the culprit occlusion and restoration of epicardial coronary flow for ST-segment elevation acute myocardial infarction STEMI results in poor outcome The investigators hypothesized that nitroprusside NTP injected intracoronary immediately before angioplasty might prevent no-reflow and improve vessel flow and myocardial perfusion
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None